Received Jul 4, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | 97D52 | — |
Adjuvant was given without being mixed with the active ingredient; Adjuvant was given without being mixed with the active ingredient; This non-serious case was reported by a other health professional and described the occurrence of inappropriate preparation of medication in a 57-year-old female patient who received Herpes zoster (Shingrix) (batch number 97D52, expiry date 16-SEP-2025) for prophylaxis. Concurrent medical conditions included hypertension, blood cholesterol increased and obesity. Concomitant products included lisinopril dihydrate (Lisinopril), atorvastatin calcium (Atorvastatin), pioglitazone hydrochloride (Pioglitazone) and tirzepatide (Mounjaro). On 07-APR-2025, the patient received Shingrix. On 07-APR-2025, an unknown time after receiving Shingrix, the patient experienced inappropriate preparation of medication (Verbatim: Adjuvant was given without being mixed with the active ingredient) and inappropriate dose of vaccine administered (Verbatim: Adjuvant was given without being mixed with the active ingredient). The outcome of the inappropriate preparation of medication and inappropriate dose of vaccine administered were not applicable. Additional Information: GSK Receipt Date: 26-JUN-2025 The reporter stated that the Shingrix adjuvant was given to the patient without being mixed with the active ingredient, which led to an inappropriate preparation of medication and inappropriate dose of vaccine administered.; Sender's Comments: US-GSK-US2025061270:same reporter differnt patient
Blood cholesterol increased; Hypertension; Obesity
LISINOPRIL; ATORVASTATIN; PIOGLITAZONE; MOUNJARO